Ertapenem sodium

Research use only, not for human use.

Ertapenem sodium is a new long-acting 1-β-methyl carbapenem antibiotic with a broad antibacterial spectrum including common aerobic and anaerobic bacteria and organisms with extended-spectrum β-lactamases.

Ertapenem sodium is a new long-acting 1-β-methyl carbapenem antibiotic with a broad antibacterial spectrum including common aerobic and anaerobic bacteria and organisms with extended-spectrum β-lactamases.(In Vitro):Ertapenem sodium (0-100 μg/mL approximately, 48 h) is active against 99.1% of all anaerobes with a mode MIC of 0.12 μg/mL and MIC90 of 1 μg/mL, and MIC’s ≥8 μg/mL for B.fragilis and B.vulgatus species, respectively.(In Vivo):Ertapenem sodium (Subcutaneous injection, 0-10 mg/kg, 0-120 h after infection, S. aureus thigh tissue infection model) shows > 3 log10 CFU reduction of organism at 10 mg/kg, and maintains the activity with 3.3 and 4.4 log10 CFU eliminated at 2 mg/kg.Ertapenem sodium (Subcutaneous injection, 4h after infection, systemic infection model) is active against all gram-positive organisms, and is also active against gram-negative organisms tested with ED50s of <0.25 mg/kg/dose.

Ertapenem sodium (0-100 μg/mL approximately, 48 h) is active against 99.1% of all anaerobes with a mode MIC of 0.12 μg/mL and MIC90 of 1 μg/mL, and MIC’s ≥8 μg/mL for B.fragilis and B.vulgatus species, respectively. Cell Viability AssayCell Line: B. fragilis (ATCC 25285), B. thetaiotaomicron (ATCC 29741), and Eubacterium lentum (ATCC 43055)Concentration:0-100 μg/mL approximately Incubation Time:48 h Result:Inhibited 99.1% of all isolate with a mode MIC of 0.12 μg/mL and MIC90 of 1 μg/mL, and 98.8% of the isolates were susceptible among the B. fragilis group.

Ertapenem sodium (Subcutaneous injection, 0-10 mg/kg, 0-120 h after infection, S. aureus thigh tissue infection model) shows > 3 log10 CFU reduction of organism at 10 mg/kg, and maintains the activity with 3.3 and 4.4 log10 CFU eliminated at 2 mg/kg.Ertapenem sodium (Subcutaneous injection, 4h after infection, systemic infection model) is active against all gram-positive organisms, and is also active against gram-negative organisms tested with ED50s of <0.25 mg/kg/dose. Animal Model:S. aureus thigh tissue infection model (DBA/2 mice)Dosage:0.5,1, 2, 5, 10 mg/kg (given at 2, 6, 10, 24, 48, 72, 96, 120 h) Administration:Subcutaneous injection (0.5 mL after infection)Result:Displayed > 3 log10 CFU reduction of organism compared to non-antibiotic-treated controls at 10 mg/kg.Maintained the activity with 3.3 and 4.4 log10 CFU eliminated at 2 mg/kg Animal Model:Systemic infection model (DBA/2 female mice, viral antibody-free CD-1 female mice)Dosage:0-3 mg/kg approximately Administration:Subcutaneous injection (0.5 mL, begin immediately and 4 h after infection)Result:Showed activity against all gram-positive organisms, and also ram-negative organisms tested with ED50s of <0.25mg/kg/dose.Animal Model:CD-1 mice, rats Dosage:10 mg/kg approximately Administration: Intraperitoneal injection (pharmacokinetic assay)Result:Exhibited an AUC0-∞ ranging from 1.8-21.82 μg?hr/mL in tissue in mice following a 10-mg/kg i.p. dose.Exhibited slow clearance rate with a t1/2β of 3.2 h, Clp of 0.47 mL/min/kg, AUC0-8 of 284.15 μg?hr/mL.

MK-826 | L-749345

Microbiology/Virology

Antibiotic

Antibiotic

Inflammation/Immunology

Bacterial infections; Community-acquired pneumonia; Intra-abdominal infections; Obstetric and gynaecological infections

153773-82-1

497.502

C22H24N3O7S.Na

>98% (HPLC)

DMSO:201 mM;water:100.5mM

[Na+].C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)Nc3cccc(c3)C([O-])=O)=C(N2C1=O)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years